TMDX - TransMedics Group Inc Stock Price, Fair Value and News

137.98USD+3.05 (+2.26%)Market Closed

Market Summary

USD137.98+3.05

Market Closed

2.26%

TMDX Alerts

6 major insider sales recently.

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)

TMDX Stock Price

View Fullscreen

TMDX RSI Chart

TMDX Valuation

Market Cap

4.5B

Price/Earnings (Trailing)

-445.78

Price/Sales (Trailing)

15.31

EV/EBITDA

361.6

Price/Free Cashflow

-22.4

TMDX Price/Sales (Trailing)

TMDX Profitability

Operating Margin

62.40%

EBT Margin

-3.92%

Return on Equity

-6.39%

Return on Assets

-1.41%

Free Cashflow Yield

-4.46%

TMDX Fundamentals

TMDX Revenue

Revenue (TTM)

296.9M

Rev. Growth (Yr)

133.07%

Rev. Growth (Qtr)

19.31%

TMDX Earnings

Earnings (TTM)

-10.2M

Earnings Growth (Yr)

562.71%

Earnings Growth (Qtr)

202.58%

Breaking Down TMDX Revenue

Last 7 days

6.2%

Last 30 days

57.1%

Last 90 days

53.4%

Trailing 12 Months

87.8%

How does TMDX drawdown profile look like?

TMDX Financial Health

Current Ratio

9.72

Debt/Equity

2.81

Debt/Cashflow

-0.02

TMDX Investor Care

Shares Dilution (1Y)

1.18%

Diluted EPS (TTM)

-0.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	296.9M	0	0	0
2023	119.1M	151.1M	191.8M	241.6M
2022	39.1M	51.4M	71.8M	93.5M
2021	25.2M	29.9M	28.2M	30.3M
2020	26.5M	24.2M	24.1M	25.6M
2019	15.2M	17.9M	21.1M	23.6M
2018	0	0	0	13.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of TransMedics Group Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 07, 2024	basile edward m	sold	-930,278	129	-7,157	-
May 06, 2024	khayal tamer i	sold	-759,479	130	-5,839	chief commercial officer
May 06, 2024	hassanein waleed h	sold	-3,902,100	130	-30,000	president & ceo
May 06, 2024	gordon stephen	acquired	576,900	38.46	15,000	chief financial officer
May 06, 2024	khayal tamer i	acquired	385,958	66.1	5,839	chief commercial officer
May 06, 2024	gordon stephen	sold	-1,920,000	128	-15,000	chief financial officer
May 06, 2024	corcoran nicholas	sold	-418,570	129	-3,222	see remarks
May 06, 2024	hassanein waleed h	acquired	398,400	13.28	30,000	president & ceo
May 03, 2024	tobin james r	sold	-1,503,690	125	-12,025	-
May 02, 2024	hassanein waleed h	sold	-1,510,870	121	-12,444	president & ceo

Which funds bought or sold TMDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-31.4	-2,605,560	4,685,210	-%
May 16, 2024	COMERICA BANK	added	1,072	969,238	1,066,360	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.04	-298,929	2,407,260	-%
May 16, 2024	Ancora Advisors LLC	unchanged	-	-2,495	36,970	-%
May 15, 2024	Dana Investment Advisors, Inc.	added	14.72	114,792	1,652,190	0.06%
May 15, 2024	JANUS HENDERSON GROUP PLC	added	0.01	-71,331	1,050,150	-%
May 15, 2024	Apis Capital Advisors, LLC	added	138	2,138,000	3,874,460	2.94%
May 15, 2024	MARSHALL WACE, LLP	reduced	-23.67	-7,698,550	19,315,600	0.03%
May 15, 2024	EVENTIDE ASSET MANAGEMENT, LLC	added	17.67	8,026,670	86,502,000	1.36%
May 15, 2024	Point72 Hong Kong Ltd	sold off	-100	-47,358	-	-%

Are Funds Buying or Selling TMDX?

Are funds buying TMDX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TMDX

No. of Funds

Unveiling TransMedics Group Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	macquarie group ltd	4.67%	1,525,793	SC 13G/A
Feb 13, 2024	vanguard group inc	5.71%	1,865,115	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 25, 2024	blackrock inc.	7.8%	2,550,255	SC 13G/A
Feb 14, 2023	macquarie group ltd	6.10%	1,947,418	SC 13G/A
Feb 10, 2023	sandhill capital partners llc	3.8%	1,203,750	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	5.30%	1,691,425	SC 13G
Feb 03, 2023	blackrock inc.	7.2%	2,310,705	SC 13G/A
Feb 02, 2023	credit suisse ag/	3.24%	1,037,297	SC 13G/A

Recent SEC filings of TransMedics Group Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4/A	Insider Trading
May 14, 2024	4/A	Insider Trading
May 10, 2024	144	Notice of Insider Sale Intent
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading

Peers (Alternatives to TransMedics Group Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

TransMedics Group Inc News

Latest updates

TransMedics Group Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	19.3%	96,850,000	81,174,000	66,430,000	52,465,000	41,554,000	31,375,000	25,683,000	20,521,000	15,880,000	9,668,000	5,370,000	8,171,000	7,053,000	7,627,000	7,091,000	3,391,000	7,530,000	6,057,000	7,205,000	5,666,000	4,676,000
Cost Of Revenue	10.9%	36,888,000	33,250,000	25,768,000	15,724,000	12,788,000	10,672,000	7,568,000	6,171,000	3,776,000	2,682,000	1,597,000	2,582,000	2,242,000	2,799,000	2,053,000	1,482,000	2,670,000	2,316,000	2,989,000	2,333,000	2,103,000
Gross Profit	25.1%	59,962,000	47,924,000	40,662,000	36,741,000	28,766,000	20,703,000	18,115,000	14,350,000	12,104,000	6,986,000	3,773,000	5,589,000	4,811,000	4,828,000	5,038,000	1,909,000	4,860,000	3,741,000	4,216,000	3,333,000	2,573,000
Operating Expenses	4.9%	47,541,000	45,321,000	68,997,000	37,647,000	30,855,000	27,482,000	23,659,000	24,095,000	21,473,000	18,314,000	15,498,000	15,457,000	11,318,000	10,724,000	9,648,000	9,770,000	12,877,000	12,435,000	11,458,000	11,038,000	8,535,000
S&GA Expenses	4.6%	36,161,000	34,560,000	30,653,000	29,356,000	24,984,000	21,726,000	16,851,000	17,381,000	13,939,000	12,000,000	10,335,000	9,162,000	6,786,000	6,176,000	5,493,000	5,867,000	6,652,000	6,173,000	6,519,000	6,251,000	4,653,000
R&D Expenses	5.8%	11,380,000	10,761,000	11,132,000	8,291,000	5,871,000	5,756,000	6,808,000	6,714,000	7,534,000	6,314,000	5,163,000	6,295,000	4,532,000	4,548,000	4,155,000	3,903,000	6,225,000	6,262,000	4,939,000	4,787,000	3,882,000
EBITDA Margin	235.6%	0.04	-0.03	-0.12	-0.05	-0.17	-0.31	-0.50	-0.81	-1.05	-1.27	-1.14	-0.81	-	-	-	-	-	-	-	-	-
Interest Expenses	-0.2%	3,598,000	3,605,000	3,590,000	2,505,000	1,091,000	1,007,000	787,000	972,000	960,000	978,000	979,000	965,000	952,000	971,000	971,000	1,001,000	1,042,000	1,063,000	1,084,000	1,113,000	1,093,000
Income Taxes	216.7%	196,000	-168,000	-1,507,000	21,000	11,000	19,000	19,000	22,000	6,000	17,000	9,000	6,000	4,000	10,000	6,000	6,000	10,000	10,000	10,000	10,000	10,000
Earnings Before Taxes	220.8%	12,393,000	3,863,000	-26,929,000	-980,000	-2,625,000	-6,701,000	-7,407,000	-11,501,000	-10,556,000	-12,651,000	-12,953,000	-10,662,000	-7,913,000	-6,301,000	-5,082,000	-8,491,000	-8,842,000	-9,167,000	-8,270,000	-9,185,000	-6,885,000
EBT Margin	64.4%	-0.04	-0.11	-0.19	-0.12	-0.24	-0.39	-0.59	-0.93	-1.20	-1.46	-1.34	-1.00	-	-	-	-	-	-	-	-	-
Net Income	202.6%	12,197,000	4,031,000	-25,422,000	-1,001,000	-2,636,000	-6,720,000	-7,426,000	-11,523,000	-10,562,000	-12,668,000	-12,962,000	-10,668,000	-7,917,000	-6,311,000	-5,088,000	-8,497,000	-8,852,000	-9,177,000	-8,280,000	-9,195,000	-6,895,000
Net Income Margin	66.9%	-0.03	-0.10	-0.19	-0.12	-0.24	-0.39	-0.59	-0.93	-1.20	-1.46	-1.34	-1.00	-	-	-	-	-	-	-	-	-
Free Cashflow	-42.1%	-47,607,000	-33,514,000	-114,590,000	-7,183,000	-9,588,000	-6,799,000	-17,212,000	-13,354,000	-20,359,000	-9,826,000	-9,418,000	-5,789,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	2.5%	724	706	689	690	287	277	275	117	124	135	131	141	146	152	159	163	97.00	105	113	121	39.00
Current Assets	-4.4%	488	511	537	663	262	252	251	95.00	106	119	126	135	141	147	154	158	92.00	100	107	116	30.00
Cash Equivalents	-11.2%	351	395	427	582	195	201	204	30.00	18.00	26.00	22.00	25.00	27.00	25.00	21.00	51.00	25.00	21.00	20.00	47.00	12.00
Inventory	9.7%	49.00	44.00	39.00	31.00	24.00	21.00	19.00	17.00	17.00	15.00	15.00	13.00	12.00	12.00	13.00	13.00	11.00	11.00	11.00	11.00	11.00
Net PPE	23.3%	214	174	131	20.00	19.00	19.00	18.00	16.00	12.00	10.00	5.00	5.00	5.00	5.00	5.00	4.00	5.00	5.00	5.00	4.00	4.00
Goodwill	0%	12.00	12.00	12.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-0.8%	564	569	563	545	94.00	90.00	87.00	66.00	64.00	67.00	53.00	52.00	48.00	48.00	50.00	49.00	50.00	51.00	49.00	50.00	51.00
Current Liabilities	-8.6%	50.00	55.00	49.00	32.00	29.00	24.00	21.00	23.00	20.00	23.00	16.00	15.00	12.00	12.00	14.00	14.00	15.00	16.00	15.00	15.00	16.00
Long Term Debt	0.2%	448	447	446	446	59.00	59.00	59.00	35.00	35.00	35.00	35.00	35.00	35.00	35.00	35.00	34.00	34.00	34.00	34.00	34.00	34.00
LT Debt, Non Current	-100.0%	-	447	446	446	59.00	59.00	59.00	35.00	35.00	35.00	35.00	35.00	35.00	35.00	35.00	34.00	34.00	34.00	34.00	34.00	34.00
Shareholder's Equity	16.2%	159	137	126	145	193	187	188	51.00	60.00	68.00	79.00	89.00	98.00	104	110	114	47.00	55.00	63.00	71.00	-
Retained Earnings	2.4%	-491	-503	-507	-482	-481	-478	-472	-464	-453	-442	-429	-416	-406	-398	-391	-386	-378	-369	-360	-352	-342
Shares Outstanding	0.6%	33.00	33.00	33.00	33.00	33.00	32.00	29.00	28.00	28.00	28.00	28.00	27.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,641	-	-	-	841	-	-	-	858	-	-	-	454	-	-	-	454	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-141.4%	-3,435	8,304	-6,868	-5,803	-8,661	-4,035	-14,282	-9,094	-18,406	-6,648	-9,350	-5,536	-7,330	-7,138	-6,412	-8,539	-8,176	-7,264	-5,597	-12,159	-7,266
Share Based Compensation	20.0%	6,870	5,724	5,188	4,958	3,921	2,991	2,704	2,316	2,310	1,985	1,973	1,808	1,112	698	700	631	385	282	295	220	57.00
Cashflow From Investing	-5.6%	-44,172	-41,818	-149,828	-1,380	-927	-2,764	24,748	22,015	10,514	9,992	6,199	3,804	9,272	9,884	-23,473	-40,724	12,715	7,360	-18,765	-49,093	-3.00
Cashflow From Financing	244.7%	3,185	924	1,523	394,013	3,958	3,065	164,220	237	405	45.00	552	213	583	33.00	-179	75,543	152	-246	-2,428	96,094	-697

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TMDX Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 96,850	$ 41,554
Cost of revenue:
Total cost of revenue	36,888	12,788
Gross profit	59,962	28,766
Operating expenses:
Research, development and clinical trials	11,380	5,871
Selling, general and administrative	36,161	24,984
Total operating expenses	47,541	30,855
Income (loss) from operations	12,421	(2,089)
Other income (expense):
Interest expense	(3,598)	(1,091)
Interest income and other income (expense)	3,570	555
Total other expense, net	(28)	(536)
Income (loss) before income taxes	12,393	(2,625)
Provision for income taxes	(196)	(11)
Net income (loss)	$ 12,197	$ (2,636)
Net income (loss) per share, basic	$ 0.37	$ (0.08)
Net income (loss) per share, diluted	$ 0.35	$ (0.08)
Weighted average common shares outstanding, basic	32,760,190	32,260,267
Weighted average common shares outstanding, diluted	34,678,895	32,260,267
Net product revenue [Member]
Revenue:
Total revenue	$ 61,325	$ 33,993
Cost of revenue:
Total cost of revenue	14,084	7,306
Service Revenue [Member]
Revenue:
Total revenue	35,525	7,561
Cost of revenue:
Total cost of revenue	$ 22,804	$ 5,482

TMDX Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 350,217	$ 394,812
Accounts receivable	81,942	63,576
Inventory	48,541	44,235
Prepaid expenses and other current assets	7,606	8,031
Total current assets	488,306	510,654
Property, plant and equipment, net	214,421	173,941
Operating lease right-of-use assets	6,226	6,546
Restricted cash	500	500
Goodwill	11,990	11,990
Acquired intangible assets, net	2,303	2,354
Other non-current assets	85	62
Total assets	723,831	706,047
Current liabilities:
Accounts payable	9,225	12,717
Accrued expenses and other current liabilities	36,852	38,221
Deferred revenue	2,060	1,961
Operating lease liabilities	2,086	2,035
Total current liabilities	50,223	54,934
Convertible senior notes, net	447,835	447,140
Long-term debt, net	59,141	59,064
Operating lease liabilities, net of current portion	7,161	7,707
Total liabilities	564,360	568,845
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, no par value; 25,000,000 shares authorized; no shares issued or outstanding
Common stock, no par value; 150,000,000 shares authorized; 32,851,376 shares and 32,670,803 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	651,161	641,106
Accumulated other comprehensive loss	(182)	(199)
Accumulated deficit	(491,508)	(503,705)
Total stockholders' equity	159,471	137,202
Total liabilities and stockholders' equity	$ 723,831	$ 706,047

About TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

CEO	Dr. Waleed H. Hassanein M.D.
WEBSITE	transmedics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	212

TransMedics Group Inc Frequently Asked Questions

What is the ticker symbol for TransMedics Group Inc? What does TMDX stand for in stocks?

TMDX is the stock ticker symbol of TransMedics Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TransMedics Group Inc (TMDX)?

As of Fri May 17 2024, market cap of TransMedics Group Inc is 4.54 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TMDX stock?

You can check TMDX's fair value in chart for subscribers.

What is the fair value of TMDX stock?

You can check TMDX's fair value in chart for subscribers. The fair value of TransMedics Group Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TransMedics Group Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TMDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TransMedics Group Inc a good stock to buy?

The fair value guage provides a quick view whether TMDX is over valued or under valued. Whether TransMedics Group Inc is cheap or expensive depends on the assumptions which impact TransMedics Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TMDX.

What is TransMedics Group Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TMDX's PE ratio (Price to Earnings) is -445.78 and Price to Sales (PS) ratio is 15.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TMDX PE ratio will change depending on the future growth rate expectations of investors.